Alyce Anderson1, Laura K Ferris2, Benjamin Click3, Claudia Ramos-Rivers3, Ioannis E Koutroubakis3, Jana G Hashash3, Michael Dunn3, Arthur Barrie3, Marc Schwartz3, Miguel Regueiro3, David G Binion4. 1. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2. Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 3. Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, M2, C-wing, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. 4. Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, M2, C-wing, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. binion@pitt.edu.
Abstract
BACKGROUND: Dermatologic manifestations of inflammatory bowel disease (IBD) are common, and certain IBD medications increase the risk of skin cancer. AIMS: To define the rates of care and factors associated with dermatologic utilization with a focus on skin cancer screening. METHODS: We utilized a prospective, natural history IBD research registry to evaluate all outpatient healthcare encounters from 2010 to 2016. Gastrointestinal, dermatologic and primary care visits per individual were identified. We calculated the proportion of patients obtaining care, categorized primary indications for dermatologic visits, determined the incidence of melanoma and non-melanoma skin cancers, and used logistic regression to determine factors associated with dermatology utilization. RESULTS: Of the 2127 IBD patients included, 452 (21.3%) utilized dermatology over the study period, and 55 (2.6%) had a total body skin examination at least once. The 452 patients incurred 1633 dermatology clinic visits, 278 dermatologic procedures, and 1108 dermatology telephone encounters. The most frequent indication was contact dermatitis or dermatitis. Factors associated with dermatology use were family history of skin cancer, employment, systemic steroids, longer disease duration, emergency room use, and the number of IBD-related clinic visits. Between 8.3 and 11% of IBD patients recommended for skin cancer screening visited dermatology each year, and the resulting incidence of non-melanoma skin cancer was 35.4/10,000 [95% CI 23.3-51.5] and melanoma was 6.56/10,000 [95% CI 2.1-15.3]. CONCLUSIONS: Less than one in ten IBD patients obtain dermatologic care. Given the increased risk of skin cancers among IBD patients, an emphasis on education, prevention, and screening merits attention.
BACKGROUND: Dermatologic manifestations of inflammatory bowel disease (IBD) are common, and certain IBD medications increase the risk of skin cancer. AIMS: To define the rates of care and factors associated with dermatologic utilization with a focus on skin cancer screening. METHODS: We utilized a prospective, natural history IBD research registry to evaluate all outpatient healthcare encounters from 2010 to 2016. Gastrointestinal, dermatologic and primary care visits per individual were identified. We calculated the proportion of patients obtaining care, categorized primary indications for dermatologic visits, determined the incidence of melanoma and non-melanoma skin cancers, and used logistic regression to determine factors associated with dermatology utilization. RESULTS: Of the 2127 IBDpatients included, 452 (21.3%) utilized dermatology over the study period, and 55 (2.6%) had a total body skin examination at least once. The 452 patients incurred 1633 dermatology clinic visits, 278 dermatologic procedures, and 1108 dermatology telephone encounters. The most frequent indication was contact dermatitis or dermatitis. Factors associated with dermatology use were family history of skin cancer, employment, systemic steroids, longer disease duration, emergency room use, and the number of IBD-related clinic visits. Between 8.3 and 11% of IBDpatients recommended for skin cancer screening visited dermatology each year, and the resulting incidence of non-melanoma skin cancer was 35.4/10,000 [95% CI 23.3-51.5] and melanoma was 6.56/10,000 [95% CI 2.1-15.3]. CONCLUSIONS: Less than one in ten IBDpatients obtain dermatologic care. Given the increased risk of skin cancers among IBDpatients, an emphasis on education, prevention, and screening merits attention.
Authors: Marcus Harbord; Vito Annese; Stephan R Vavricka; Matthieu Allez; Manuel Barreiro-de Acosta; Kirsten Muri Boberg; Johan Burisch; Martine De Vos; Anne-Marie De Vries; Andrew D Dick; Pascal Juillerat; Tom H Karlsen; Ioannis Koutroubakis; Peter L Lakatos; Tim Orchard; Pavol Papay; Tim Raine; Max Reinshagen; Diamant Thaci; Herbert Tilg; Franck Carbonnel Journal: J Crohns Colitis Date: 2015-11-27 Impact factor: 9.071
Authors: Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren Journal: Can J Gastroenterol Date: 2005-09 Impact factor: 3.522
Authors: Ali M Abbas; Rawaa M Almukhtar; Edward V Loftus; Gary R Lichtenstein; Nabeel Khan Journal: Am J Gastroenterol Date: 2014-09-23 Impact factor: 10.864
Authors: Siddharth Singh; Sajan Jiv Singh Nagpal; Mohammad H Murad; Siddhant Yadav; Sunanda V Kane; Darrell S Pardi; Jayant A Talwalkar; Edward V Loftus Journal: Clin Gastroenterol Hepatol Date: 2013-05-02 Impact factor: 11.382